MedCity News
FEBRUARY 23, 2024
Pharmacies across the country are facing disruptions following a cyberattack on Change Healthcare — which is owned by Optum, a subsidiary of UnitedHealth Group. In a filing with the SEC, UnitedHealth stated that the unauthorized party that gained access to Change Healthcare’s systems was a “suspected nation-state associated cyber security threat actor.
Fierce Pharma
FEBRUARY 23, 2024
Even Alexander Hardy, the former Genentech leader who managed the blockbuster hemophilia drug Hemlibra, can’t immediately bend the laggard launch trajectory of BioMarin’s gene therapy Roctavian.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MedCity News
FEBRUARY 23, 2024
AI can improve the prior authorization process, but there needs to be more transparency, experts said during a recent panel held by KFF.
PharmaVoice
FEBRUARY 23, 2024
Following Moderna’s COVID-19 vaccine success, therapeutics head Dr. Kyle Holen discusses scaling mRNA development to bring candidates to the finish line in oncology and more.
Speaker: Jesse Hunter and Brynn Chadwick
Today’s buyers expect more than generic outreach–they want relevant, personalized interactions that address their specific needs. For sales teams managing hundreds or thousands of prospects, however, delivering this level of personalization without automation is nearly impossible. The key is integrating AI in a way that enhances customer engagement rather than making it feel robotic.
MedCity News
FEBRUARY 23, 2024
The benefits of artificial intelligence in healthcare are apparent. With careful planning, we can ensure that these developments benefit everyone, leaving no one behind in the goal of a healthier and more equal future.
Pharma Rep Focus brings together the best content for pharma rep professionals from the widest variety of industry thought leaders.
MedCity News
FEBRUARY 23, 2024
GSK and Vir Biotechnology have ended their influenza collaboration, a move that follows last year’s Phase 2 failure for one of the partnered programs. Vir is now free to continue its flu research on its own, but the company says it’s actively pursuing other partners.
Fierce Pharma
FEBRUARY 23, 2024
As the Biden administration’s exploration of “march-in rights" draws support from powerful entities like the Federal Trade Commission (FTC), a group of lawmakers on both sides of the aisle have war | As the Biden administration’s exploration of “march-in rights" draws support from powerful entities like the Federal Trade Commission, a small group of lawmakers on both sides of the aisle have warned the approach could “hamstring” U.S. innovation.
MedCity News
FEBRUARY 23, 2024
The conference, scheduled for May 21-22 at the Ritz Carlton hotel in Chicago, brings together healthcare investors, startups, and innovative-minded executives. Register today!
Fierce Pharma
FEBRUARY 23, 2024
Teva and Alvotech have braved a long and winding road on the quest to win approval for their biosimilar to AbbVie’s Humira. | Teva and Alvotech have braved a long and winding road on the quest to win approval for their biosimilar to AbbVie’s Humira. Now, after multiple manufacturing setbacks, the partners have finally scored their inaugural regulatory nod in the United States.
Advertiser: ZoomInfo
Incorporating generative AI (gen AI) into your sales process can speed up your wins through improved efficiency, personalized customer interactions, and better informed decision- making. Gen AI is a game changer for busy salespeople and can reduce time-consuming tasks, such as customer research, note-taking, and writing emails, and provide insightful data analysis and recommendations.
Pharma IQ
FEBRUARY 23, 2024
Bringing a new drug to market typically takes a decade or more and approximately US$2.5 billion. However, new technology, including AI, can dramatically shorten the drug discovery process and reduce t.
Fierce Pharma
FEBRUARY 23, 2024
Following a contentious advisory committee meeting and an FDA request for the withdrawal of Oncopeptides’ multiple myeloma drug Pepaxto from the U.S. | Following a contentious advisory committee meeting and an FDA request for withdrawal of Oncopeptides’ multiple myeloma drug Pepaxto from the U.S. market in late 2022, the other shoe has dropped.
Pharma IQ
FEBRUARY 23, 2024
Explore how AI/ML can accelerate rare disease research and clinical trials, by enhancing inclusivity and efficiency, to deliver new drugs and therapeutics to patients. With insights from Dr. Harsha Ra.
Fierce Pharma
FEBRUARY 23, 2024
This week on “The Top Line,” we explore the impact of environmental, social and governance measures, commonly known as ESG, on the pharmaceutical industry. | This week on "The Top Line," we explore the impact of environmental, social, and governance measures, commonly known as ESG, on the pharmaceutical industry. Fierce Pharma's Fraiser Kansteiner engages in a conversation with Jim Greffet, Head of ESG Strategy at Eli Lilly, to gain insights and discuss Lilly's specific ESG
Speaker: Kevin Burke
AI is reshaping marketing and sales, empowering professionals to work smarter, faster, and more effectively. This webinar will provide a practical introduction to AI, focusing on its current applications, transformative potential, and strategies for successful implementation in your organization. Using real-world examples and actionable insights, we’ll examine how businesses are leveraging AI to increase efficiency, enhance personalization, and drive measurable results.
PharmaVoice
FEBRUARY 23, 2024
The company earned only $3.5 million last year from its Roctavian treatment, far below the $50 million to $150 million range it had forecast eight months ago.
pharmaphorum
FEBRUARY 23, 2024
Bavarian Nordic will get an accelerated review of its chikungunya vaccine CHIKV VLP at the EMA, as it tries to chase down a lead held by rival Valneva. The Danish pharma group said it is planning to file for approval of its vaccine in the first half of this year, adding the EU regulator’s human medicine committee, the CHMP, has said it will cut the review time from 210 to 150 days under its accelerated assessment procedure.
PharmaTimes
FEBRUARY 23, 2024
The immunosuppressant reduced inflammation in patients with the skin condition after three days
pharmaphorum
FEBRUARY 23, 2024
AI software developed by Israeli medtech Magentiq-Eye has been shown to improve detection rates for adenoma, a precursor to colorectal cancer, in colonoscopy procedures
Advertiser: ZoomInfo
In today’s ultra-competitive markets, it’s no longer enough to wait for buyers to show obvious signs of interest. Instead, sales teams must be proactive, identifying and acting on nuanced buyer behaviors — often before prospects are fully ready to make a purchase. In this eBook from ZoomInfo & Sell Better, learn 10 actionable ways to use these buyer signals to transform your sales strategy and close deals faster.
PharmaTimes
FEBRUARY 23, 2024
In England, around 1,100 cases of bowel cancer are caused by the inherited condition every year
pharmaphorum
FEBRUARY 23, 2024
The FDA has started a priority review of Sanofi and Regeneron’s Dupixent as a treatment for chronic obstructive pulmonary disease (COPD), which could become the first new treatment for the widespread and life-threatening disease in over a decade.
Pharmaceutical Technology
FEBRUARY 23, 2024
The FDA Office of Generic Drugs reported a rise in generic drug approvals, as several first-time generics entered the market.
pharmaphorum
FEBRUARY 23, 2024
After losing Roche as a partner, Blueprint Medicines has sold US commercial rights to RET inhibitor Gavreto to Rigel Pharma in a deal worth up to $117.
Advertisement
What if you could help your sellers stop wasting 72% of their day on non-selling activities and focus on bringing in revenue? Incorporating AI in your enablement workflows can help you cut down on busy work, get projects done faster, and let your team (and you!) focus on making a bigger impact. We put together this guide to show you how to use AI to cut time and costs for projects, including collateral creation, development of training videos, and automating tedious processes.
Pharmaceutical Commerce
FEBRUARY 23, 2024
A cross-sectional study investigates how this supply chain link helps increase Medicare Part D spending on self-administered specialty drugs.
pharmaphorum
FEBRUARY 23, 2024
Travere and partner CSL Vifor close on EU approval of sparsentan for rare kidney disease IgA nephropathy, after CHMP's positive opinion on the drug.
European Pharmaceutical Review
FEBRUARY 23, 2024
An interim analysis of a Phase III trial has demonstrated superior efficacy of the long-acting injectable antiretroviral treatment (ART) for HIV, Cabenuva ( cabotegravir + rilpivirine), for HIV patients with a history of ART adherence challenges. “The interim data indicating the superiority of long-acting therapy compared to daily oral therapy in individuals who have difficulty taking pills for HIV every day is a remarkable outcome,” shared Dr Kimberly Smith, MPH, Head of R&D at ViiV Healt
Pharmacy Times
FEBRUARY 23, 2024
The evolution of pharmacy, as a practice and profession, is unique in that its evolution has quickened exponentially in just the past 20 years.
Advertiser: ZoomInfo
As prospects define their problem, search for solutions, and even change jobs, they are generating high-value signals that the best go-to-market teams can leverage to close more deals. This is where signal-based selling comes into play. ZoomInfo CEO Henry Schuck recently broke down specific ways to put four key buying signals into action with the experts from 30 Minutes to President’s Club.
European Pharmaceutical Review
FEBRUARY 23, 2024
AbbVie’s current President and Chief Operating Officer (COO) is set to replace the company’s existing CEO later this year. Robert Michael will become AbbVie’s new CEO on 1 July 2024. Richard Gonzalez will retire as the company’s CEO to become Executive Chairman, having served as the company’s CEO since its launch in 2013, AbbVie noted.
Copyright Clearance Center
FEBRUARY 23, 2024
The post Navigating the Future: Experts Discuss the Intersection of Copyright, AI, and Innovation in Upcoming Virtual Town Hall appeared first on Copyright Clearance Center.
Pharmaceutical Technology
FEBRUARY 23, 2024
The UK NICE has recommended Pfizer's Ritlecitinib as a new treatment option for individuals suffering from alopecia areata.
Expert insights. Personalized for you.
322 
Let's personalize your content